Program
nemtabrutinib
In Merck's pipeline, Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of onc
. Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Hematologic Neoplasms · Renal Insufficiency · Lymphoma, Large B-Cell, Diffuse, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 167 open or running | phase 3since Nov 14, 2022 | May 15, 2017 | Feb 1, 2027phase 1 · NCT07734610 |
- Named in Merck’s own pipeline as
nemtabrutinib (MK-1026)
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2017First study: phase 2 study in Lymphoma, B-CellFirst studyNCT03162536 · 190 enrolled · United States
- Jan 25, 2021Phase 2 study in Hematologic NeoplasmsNCT04728893 · 490 planned · United States, Argentina, Australia and more
- Apr 20, 2022Phase 1 study in Hematologic NeoplasmsNCT05347225 · 12 enrolled · China
- Nov 14, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05624554 · 300 enrolled · United States, Australia, Brazil and more
- Jan 4, 2023Phase 1 study in Mature B-cell NeoplasmsNCT05673460 · 7 enrolled · Japan
- Jul 7, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05947851 · 735 planned · United States, Argentina, Australia and more
- Nov 13, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06136559 · 1,200 planned · United States, Australia, Belgium and more
- May 29, 2024Phase 1 study in Hepatic Impairment (HI)NCT06442436 · 24 enrolled · United States
- Sep 4, 2024Phase 1 study in Hematologic NeoplasmsNCT06586671 · 40 enrolled · United States
- Oct 1, 2024Phase 1 study in HealthyNCT06625827 · 24 enrolled · United States
- Nov 12, 20242 phase 1 studies in HealthyNCT06688045, NCT06698016
- Jan 9, 20252 phase 1 studies in HealthyNCT06772818, NCT06772805
- Nov 14, 2025Phase 1 study in HealthyNCT07232589 · 26 enrolled · United States
- Jul 20, 2026Phase 1 study in Renal InsufficiencyNCT07734610 · 20 planned · United States
Ahead
- Feb 1, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07734610
- Apr 30, 2027Primary completion: phase 1 study in Hematologic NeoplasmsNCT05347225
- May 19, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05624554
- Sep 17, 2027Primary completion: phase 2 study in Lymphoma, B-CellNCT03162536
TargetBeta
“Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of onc”the company's pipeline, read by Claude · source
“An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07734610Renal Insufficiency · United States | 1 | Recruiting | Feb 1, 2027 | 20 |
| NCT07232589Healthy · United States | 1 | Completed | May 4, 2026 | 26 |
| NCT06772818Healthy · United States | 1 | Completed | Dec 20, 2023 | 20 |
| NCT06772805Healthy · United States | 1 | Completed | Dec 12, 2023 | 18 |
| NCT06698016Healthy · United States | 1 | Completed | Oct 30, 2023 | 16 |
| NCT06688045Healthy · United States | 1 | Completed | Jan 6, 2024 | 15 |
| NCT06625827Healthy · United States | 1 | Completed | Jan 22, 2024 | 24 |
| NCT06586671Hematologic Neoplasms · United States | 1 | Completed | Nov 13, 2023 | 40 |
| NCT06442436Hepatic Impairment (HI) · United States | 1 | Completed | Aug 13, 2026 | 24 |
| NCT06136559Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Recruiting | Sep 7, 2032 | 1,200 |
| NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Jun 1, 2032 | 735 |
| NCT05673460Mature B-cell Neoplasms · Japan | 1 | Completed | Apr 28, 2025 | 7 |
| NCT05624554Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Active, not recruiting | May 19, 2027 | 300 |
| NCT05347225Hematologic Neoplasms · China | 1 | Active, not recruiting | Apr 30, 2027 | 12 |
| NCT04728893Hematologic Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Jan 4, 2029 | 490 |
| NCT03162536Lymphoma, B-Cell · United States | 2 | Active, not recruiting | Sep 17, 2027 | 190 |
How it is read
Names in the registry
- “Nemtabrutinib”, 16 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 3 studies
- Hematologic Neoplasms, 3 studies
- Renal Insufficiency, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.